Cargando…

Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial

BACKGROUND: Fatigue is a common symptom in people with multiple sclerosis (pwMS) that significantly impairs quality of life. Bright light therapy may be a cheap treatment option with little to no adverse events. OBJECTIVES: To evaluate the effectiveness of bright light therapy as a treatment option...

Descripción completa

Detalles Bibliográficos
Autores principales: Voggenberger, Lisa, Böck, Marion, Moser, Doris, Lorbeer, Gudrun, Altmann, Patrick, Leutmezer, Fritz, Berger, Thomas, Seidel, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647309/
https://www.ncbi.nlm.nih.gov/pubmed/36387033
http://dx.doi.org/10.1177/20552173221133262
_version_ 1784827360248332288
author Voggenberger, Lisa
Böck, Marion
Moser, Doris
Lorbeer, Gudrun
Altmann, Patrick
Leutmezer, Fritz
Berger, Thomas
Seidel, Stefan
author_facet Voggenberger, Lisa
Böck, Marion
Moser, Doris
Lorbeer, Gudrun
Altmann, Patrick
Leutmezer, Fritz
Berger, Thomas
Seidel, Stefan
author_sort Voggenberger, Lisa
collection PubMed
description BACKGROUND: Fatigue is a common symptom in people with multiple sclerosis (pwMS) that significantly impairs quality of life. Bright light therapy may be a cheap treatment option with little to no adverse events. OBJECTIVES: To evaluate the effectiveness of bright light therapy as a treatment option for MS-related fatigue. METHODS: This was randomized sham-controlled trial including 26 pwMS with a Fatigue Severity Scale (FSS) Score ≥36. Participants were assigned to receive either bright white light therapy (n = 13) or dim red light (sham-intervention; n = 13). Participants used the respective intervention for 30 min each morning for two weeks, followed by a two-week washout period. The primary endpoint was the difference in FSS scores following light treatment as calculated by analysis of covariance. RESULTS: There was no significant difference in FSS (F(1,23) = 2.39, p = .136, partial ⴄ(2) = .094). However, FSS scores generally improved over the course of the study in a clinically relevant manner. CONCLUSION: Bright light therapy decreased FSS scores over the course of this study. However, this effect was not significant in comparison to a sham intervention.
format Online
Article
Text
id pubmed-9647309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-96473092022-11-15 Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial Voggenberger, Lisa Böck, Marion Moser, Doris Lorbeer, Gudrun Altmann, Patrick Leutmezer, Fritz Berger, Thomas Seidel, Stefan Mult Scler J Exp Transl Clin Original Research Article BACKGROUND: Fatigue is a common symptom in people with multiple sclerosis (pwMS) that significantly impairs quality of life. Bright light therapy may be a cheap treatment option with little to no adverse events. OBJECTIVES: To evaluate the effectiveness of bright light therapy as a treatment option for MS-related fatigue. METHODS: This was randomized sham-controlled trial including 26 pwMS with a Fatigue Severity Scale (FSS) Score ≥36. Participants were assigned to receive either bright white light therapy (n = 13) or dim red light (sham-intervention; n = 13). Participants used the respective intervention for 30 min each morning for two weeks, followed by a two-week washout period. The primary endpoint was the difference in FSS scores following light treatment as calculated by analysis of covariance. RESULTS: There was no significant difference in FSS (F(1,23) = 2.39, p = .136, partial ⴄ(2) = .094). However, FSS scores generally improved over the course of the study in a clinically relevant manner. CONCLUSION: Bright light therapy decreased FSS scores over the course of this study. However, this effect was not significant in comparison to a sham intervention. SAGE Publications 2022-11-07 /pmc/articles/PMC9647309/ /pubmed/36387033 http://dx.doi.org/10.1177/20552173221133262 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Voggenberger, Lisa
Böck, Marion
Moser, Doris
Lorbeer, Gudrun
Altmann, Patrick
Leutmezer, Fritz
Berger, Thomas
Seidel, Stefan
Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial
title Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial
title_full Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial
title_fullStr Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial
title_full_unstemmed Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial
title_short Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial
title_sort bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: a randomized sham-controlled trial
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647309/
https://www.ncbi.nlm.nih.gov/pubmed/36387033
http://dx.doi.org/10.1177/20552173221133262
work_keys_str_mv AT voggenbergerlisa brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial
AT bockmarion brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial
AT moserdoris brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial
AT lorbeergudrun brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial
AT altmannpatrick brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial
AT leutmezerfritz brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial
AT bergerthomas brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial
AT seidelstefan brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial